MASCC/ISOO International Symposium

In the first large pediatric study of adding aprepitant to standard prophylaxis for CINV, researchers have found aprepitant to be significantly more effective than a comparator placebo-added regimen in preventing this complication in children.

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline in LBM observed with placebo for patients with NSCLC.

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based (non-AC) moderately emetogenic chemotherapy (MEC).

NEPA, a treatment intended to control CINV that combines netupitant and palonosetron, demonstrated superior activity in complete response rates (from 0 to 120 hours) over oral palonosetron monotherapy.